HCA Raises 2025 Guidance Following Strong Q3 2025 Profit Growth

HCA Healthcare (HCA.US) reported robust financial results for the third quarter ended September 30, 2025, with revenues reaching $19.161 billion, marking a 9.6% increase year-over-year. Net income attributable to HCA Healthcare, Inc. saw a significant rise of 29.4% to $1.643 billion, translating to diluted earnings per share (EPS) of $6.96, a 42.6% increase compared to the prior year. The company's diluted EPS of $6.96 exceeded analyst estimates of $5.65.

Operational Performance Drives Growth

The company's strong performance was driven by solid operational metrics, with same facility admissions increasing by 2.1% and same facility equivalent admissions rising by 2.4% in the third quarter of 2025 compared to the same period last year. Same facility revenue per equivalent admission also saw a healthy increase of 6.6%. These improvements reflect effective execution of the company's strategy to enhance patient access and invest in advanced technology.

Updated 2025 Guidance Reflects Optimism

Following these strong results, HCA Healthcare updated its 2025 full-year guidance, raising expectations for revenues, net income, and EPS. The company now anticipates 2025 revenues to be between $75.000 billion and $76.500 billion, and diluted EPS to range from $27.00 to $28.00 per diluted share. This upward revision signals management's confidence in continued operational excellence and market conditions.

Capital Allocation and Shareholder Returns

HCA Healthcare demonstrated its commitment to shareholder returns through significant capital allocation initiatives. During the third quarter of 2025, the company repurchased 6.514 million shares of its common stock at a cost of $2.498 billion, with $3.256 billion remaining under its repurchase authorization. Additionally, the Board of Directors declared a quarterly cash dividend of $0.72 per share, payable on December 29, 2025.